Rodman & Renshaw

Rodman & Renshaw raises its target on Outperform-rated Northern Oil and Gas (NYSE: NOG) to $34, up $4, on higher Bakken and Three Forks upside assumptions. Rodman & Renshaw comments, "Leading operators have been assuming up to 8 wells per unit (4 Bakken and 4 TF) in the play, but the...

Rodman & Renshaw raises its rating on Outperform-rated Magnum Hunter Resource (NYSE: MHR) to $8.50, up half a dollar, as it adjusts estimates on higher commodity price realization. Rodman & Renshaw says, "Higher forecast commodity price realizations and lower forecast per-unit LOE (...

Rodman & Renshaw raises its price target on Outperform-rated Rosetta Resources (NYSE: ROSE) to $68 a share on higher PV10 value and increased Eagle Ford Assumptions. Rodman & Renshaw notes, "ROSE announced year-end reserves of 161 MMBoe (54% liquids, 64% PUDs), roughly in line with our...

According to Rodman & Renshaw, Carrizo Oil and Gas (NASDAQ: CRZO) price target is lowered to $37. Rodman & Renshaw said that CRZO reported Q4 operating EPS of $0.23, missing the $0.32 estimate and the $0.33 consensus. “Operating EPS excludes $1.4 million of unrealized derivative gains, $5....

Rodman & Renshaw maintained its ARIAD Pharmaceuticals (NASDAQ: ARIA) Market Outperform rating and $18 price target in a research report published today. In the report, Rodman & Renshaw stated, "We continue to believe investors have not realized the full economic potential of ponatinib, or...

Rodman & Renshaw reiterates its Perform rating on BioSante Pharmaceuticals (NASDAQ: BPAX) as the company's GVAX Pancreas vaccine shows 60 percent improvement. Rodman & Renshaw notes, "Today, BioSante announced results from a Phase 1b clinical study in 30 patients with previously treated...

According to Rodman & Renshaw, Gulfport Energy (NASDAQ: GPOR) Rodman & Renshaw said that GPOR reported Q4 EPS of $0.59, below its $0.60 estimate but above the $0.58 consensus. Higher-than-expected DD&A drove the shortfall. CFPS of $1.02 topped our $0.90 estimate and the $0.88...

According to Rodman & Renshaw, Goodrich Petroleum (NYSE: GDP) price target is lowered to $22. Rodman & Renshaw said that GDP reported a Q4 operating loss of $0.38, missing our estimate of a $0.33 loss and consensus expectations of a $0.21 loss. he operating loss excludes a $6.9 million...

According to Rodman & Renshaw, Stone Energy (NYSE: SGY) price target is raised to $38. Rodman & Renshaw said that SGY reported Q4 EPS of $0.93, topping our estimate of $0.92 as well as the consensus of $0.84. “CFPS of $3.14 handily beat both our estimate of $2.71 and the consensus of $2.63...

According to Rodman & Renshaw, Vivus (NASDAQ: VVUS) is upgraded to Outperform. Rodman & Renshaw said that he FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 20-2 in favor of a recommendation for approval for VVUS' obesity drug, Qnexa. “These concerns were...

According to Rodman & Renshaw, Manitex International (NASDAQ: MNTX) price target is raised to $10. Rodman & Renshaw said that it is raising its estimates for Manitex International due to what it believes are increasingly favorable trends in the company's key end markets, particularly in...

Rodman & Renshaw maintained its Synta Pharmaceuticals (NASDAQ: SNTA) Market Perform and $8 price target in a research report published today. In the report, Rodman & Renshaw states, "Although the stock has had a nice move up of more than 30% from the low of $4.26 in early January into the...

Rodman & Renshaw reiterates its Outperform rating on Magnum Hunter Resources (NYSE: MHR) and raises its price target to $8 on further acquisition that adds to the company's Utica position. Rodman & Renshaw notes, "MHR acquired ~12,200 net acres located predominately in Noble County, OH,...

Rodman & Renshaw reiterates its Outperform rating on Magic Software Enterprises (NASDAQ: MGIC) and raises its price targe to $10 from $8, driven by expectations of continued business growth. Rodman & Renshaw notes, "The company grew revenues and net income by 28% and 60% in 2011. After...

Rodman & Renshaw trims its price target on Perform-rated Rex Energy (NASDAQ: REXX) to $18 from $19 following a new equity offering that leads to a share dilution of 18 percent. Rodman & Renshaw says, "REXX recently completed an 8.05 million share equity offering at $9.25/share; the deal...